E222: Why Most Pharma AI Will Fail Without This One Thing
About this episode
Dr Andree Bates discusses with Lisa Downey the critical importance of high-quality data for the success of AI in pharma.
Most pharma companies are racing to apply AI across drug discovery, development and commercialisation, but many of those efforts will fail for one simple reason: the data underneath is not good enough. In this episode, Dr Andree Bates speaks with Lisa Downey, CEO of DrugBank, about why trusted, structured biomedical intelligence is the foundation pharma AI cannot succeed without. Lisa explains how DrugBank has spent 20 years building and continuously curating a biomedical knowledge layer across drugs, targets, diseases and trials. With more than 156 million structured data points and over 60,000 academic citations, DrugBank is not just another dataset. It is a continuously maintained reference system designed so AI can reason over biomedical knowledge with traceability and trust. The conversation explores why most pharma AI projects fall short. Lisa argues the blocker is rarely the model. Instead, teams hit the wall because internal data lakes are not harmonised, licensed third-party data may not be AI-ready, and public data sources are incomplete or not maintained for enterprise use. Brilliant ML teams then spend most of their time cleaning and reconciling data instead of…
More episodes of AI For Pharma Growth
- E226: The AI Deal Scout: How Machine Intelligence Is Reshaping Biopharma Business Development
- E225: The 80% Nobody Talks About: Building AI Governance That Survives a Pharma Audit
- E224: The Diagnostic Room: The Financial Case Your CFO Actually Needs to See Before Approving Your AI Strategy
- E223: From Population Models to Personal Intelligence: Rethinking Biological Data
Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.